Replies to post #102091 on Ayala Pharmaceuticals Inc (ADXS)

[jaxstraw]

No surprise the stock cratered yesterday. In addition to a bull trap orchestrated masterfully by a fund or two, they got help from the ADXS management. Two PRs within few days and we now go back to low 20s.

I have been in and out of this stock for about a decade.
Way back when I was just about the only poster with a handful of others I truly believed this to be a long term hold investment.
Within a couple of years of watching it constantly being used as a teaders playground I decided it wasn't worth ever sitting on shares hoping for a big payday.
That doesn't mean I didn't see value in the platform or the science.
It just meant I wasn't going to sacrifice my money patiently waiting for it.
I would take a binary approach....invest and pull out if there were enough gains....and invest and hope that if it it while I waited for temporary gains it would be a lottery win.
But I wouldn't sit endlessly through the constant traders playground with this stock.
If I was out temporarily when the 'big news' hit I would have to deal with trying a different strategy to re-enter.
The 'big news' would be long term success...and that still would make it a desirable holding even after missing the initial price explosion.
So I enter and leave with the swings of the traders playground this has always been.
Why they have targeted this company for over a decade is a mystery to me but they have....and certain entities (I believe) have used this an ATM for years. While I don't think the company is complicit presently I have my suspicion of back in the Thomas Moore days and possibly though that regime is gone the practice of working this as traders is still here.
I hope to hot that payday someday....but I will never sit on any holdings here through a rise in share price on no news.
Take the profit.

[raja48185]

I was really puzzled about the collaboration that ADXS and Vaithi Arumugaswami's lab announced yesterday. Several points:
1) UCLA's Vaithi Arumugaswami has no background or expertise in GBM. Look at his CV, lab profile and see that he's a veterinarian, completed his PhD cell biology and worked on ZIKA virus.
https://bio.csmc.edu/view/14998/Vaithilingaraja-Arumugaswami.aspx
2) The funding of this "collab" is going to be an issue. Obviously, Arumugaswami has no internal funding for this project, and the pre-clinical work will likely be funded by ADXS once again. Instead of being laser focused on HOT and NEO, they now started this glioblastoma exploration? Did we just forget they canned several clinical programs (Aim2Cerv included) to save cash? Now they want to through good money after some decades away project? What the heck that is supposed to mean?

I strongly suspect that ADXS went ahead and teamed up with him because he has published some research papers with one guy named 'Ignatius'.

See sample below.

Publications

Click here for a list of peer-reviewed publications.

Ignatius Irudayam J, Contreras D, Spurka L, Subramanian A, Allen J, Ren S, Kanagavel V, Nguyen Q, Ramaiah A, Ramamoorthy K, French SW, Klein AS, Funari V, Arumugaswami V. Characterization of type I interferon pathway during hepatic differentiation of human pluripotent stem cells and hepatitis C virus infection. Stem Cell Res. 2015;15(2):354-364.

[ignatiusrielly35]

What leads you to believe that the institution is not funding this research? I agree that if ADXS is footing the bill it makes little sense but I’m not sure of the basis of this conclusion.

[Inoviorulez]

yes very disappointing. I was thinking that the prostate cancer data would take it higher but that didn't happen. Problem is too many are selling to make pennies. That news alone should have brought the stock to .70 cents or higher. Then the dissapointment came with the partnership announced. I thought it would be with big pharma for an upfront payment and milestones but that didn't happen. That's likely the reason for the drop. I concede to my colleagues here and will admit I was wrong. This appears to be a pure day trading playground stock.